Bret Jensen

|RSS

Currently the editor of "The Biotech Forum," Bret Jensen was chief investment strategist for Simplified Asset Management (S.A.M.), a small long/short hedge fund based in Miami, from 2008-2011. The fund was in the top 5% of long/short hedge funds for total return in its first full year (2009), as ranked by Hedgeco fund database (more than 450 funds in category). Prior to this, he spent a decade as technology director of a Fortune 100 firm.Expand

Jensen has been a top-5%-ranked financial analyst and blogger since 2013, according to TipRanks. He holds a Bachelor of Science degree in finance from Arizona State University.

Follow Bret on Twitter: @Bret_Jensen.Collapse

By

Bret Jensen

 | Jun 24, 2016 | 12:06 PM EDT
Markets have stabilized after deep early losses and major indices are sporting three percent losses across the board on the major indices. Pound as...
By

Bret Jensen

 | Jun 24, 2016 | 7:29 AM EDT

But I will be looking to add to my positions.

By

Bret Jensen

 | Jun 23, 2016 | 11:00 AM EDT

It's understandable why voters want Brexit, but it would be bad for markets.

By

Bret Jensen

 | Jun 23, 2016 | 9:52 AM EDT
Market up big as investors seem more than confident of a "Stay" vote in the U.K. referendum today despite polls that are very close albeit in favor...
By

Bret Jensen

 | Jun 22, 2016 | 12:11 PM EDT
Market posted decent day across the board as we are less than 24 hours away from the big Brexit vote. Biotech staged a whole reversal around 10am...
By

Bret Jensen

 | Jun 21, 2016 | 1:11 PM EDT
Market still holding onto slight gains as we pass the midday mark of the trading day. Biotech is down substantially, almost two percent, but is off...
By

Bret Jensen

 | Jun 21, 2016 | 12:00 PM EDT

Either way, 'leave' or 'stay,' Brexit vote likely won't affect economic environment.

By

Bret Jensen

 | Jun 21, 2016 | 10:21 AM EDT
Market is slightly up as equities try to follow up on yesterday's solid rally. I don't see significant upside in market until we get confirmation...
By

Bret Jensen

 | Jun 20, 2016 | 12:00 PM EDT

Large biotech stocks are still at their cheapest valuations since 2011.

By

Bret Jensen

 | Jun 20, 2016 | 8:34 AM EDT
Looks like we can put on our "rally caps" to begin the week, as new polling in the U.K. is showing the "remain" camp with a slight lead at moment....

BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.